Author:
Schalkwijk Stein,Sahota Tarjinder,Verheijen Remy B.,Harmer Alexander R.,Ahmed Ghada F.
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Schuller AG, Barry ER, Jones RD, Henry RE, Frigault MM, Beran G, et al. The MET inhibitor AZD6094 (savolitinib, HMPL-504) induces regression in papillary renal cell carcinoma patient-derived xenograft models. Clin Cancer Res. 2015;21(12):2811–9.
2. Gavine PR, Ren Y, Han L, Lv J, Fan S, Zhang W, et al. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models. Mol Oncol. 2015;9(1):323–33.
3. Henry RE, Barry ER, Castriotta L, Ladd B, Markovets A, Beran G, et al. Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation. Oncotarget. 2016;7(36):57651–70.
4. Jones RE, Oh S, Grimstead JW, Zimbric J, Roger L, Heppel NH, et al. Escape from telomere-driven crisis is DNA ligase III dependent. Cell Rep. 2014;8(4):1063–76.
5. Lu S, Fang J, Cao L, Li X, Guo Q, Zhou J, et al. Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. Cancer Res. 2019;79(13 Supplement):CT031–CT (Abstract CT).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献